Compare CDIO & FRSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDIO | FRSX |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1M | 5.1M |
| IPO Year | 2021 | 2016 |
| Metric | CDIO | FRSX |
|---|---|---|
| Price | $1.86 | $0.92 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 29.1K | ★ 89.7K |
| Earning Date | 11-11-2026 | 10-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $14,825.00 | N/A |
| Revenue This Year | $168,534.06 | $90.14 |
| Revenue Next Year | N/A | $154.13 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.97 | $0.78 |
| 52 Week High | $7.91 | $3.00 |
| Indicator | CDIO | FRSX |
|---|---|---|
| Relative Strength Index (RSI) | 45.06 | 29.37 |
| Support Level | $1.86 | $0.83 |
| Resistance Level | $2.14 | $1.14 |
| Average True Range (ATR) | 0.12 | 0.09 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 5.26 | 0.64 |
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.
Foresight Autonomous Holdings Ltd is a technology company engaged in the development of 3D perception systems and cellular-based applications. The company designs, develops, and commercializes in-line-of-sight vision systems and beyond-line-of-sight accident prevention solutions through its subsidiaries. Its solutions are based on stereo vision, 3D perception, and V2X technologies, aimed at improving safety by enabling accurate obstacle detection and real-time alerts. The company targets multiple industries, including automotive, defense, agriculture, and heavy equipment.